All Updates

All Updates

icon
Filter
Partnerships
Proscia partners with Nucleai to expand AI biomarker solutions for precision medicine
Precision Medicine
Jun 25, 2024
This week:
Partnerships
Sheeva.AI and P97 Networks partner for in-car payment solutions at fuel stations
Auto Tech
Today
Product updates
Food Cycle Science launches 'Food Cycler Eco 3,' a household food waste processing bin
Food Waste
Yesterday
Partnerships
Von Holzhausen and Herman Miller partner to launch plant-based leather Eames Chair
Bio-based Materials
Yesterday
Partnerships
Volvo Cars partners with Beijing Shougang and Zhejiang Yiyun for automotive steel recycling
Waste Recovery & Management Tech
Yesterday
Funding
LanzaJet receives strategic investment from Airbus
Carbon Capture, Utilization & Storage (CCUS)
Yesterday
Funding
LanzaJet receives strategic investment from Airbus
Alternative Energy
Yesterday
Partnerships
Odie Pet Insurance partners with Insuritas to offer pet coverage through financial institutions
Pet Care Tech
Yesterday
Partnerships
Odie Pet Insurance partners with Insuritas to offer pet coverage through financial institutions
InsurTech: Personal Lines
Yesterday
M&A
Applied Systems acquires Planck for undisclosed sum to expand AI capabilities
InsurTech: Infrastructure
Yesterday
Product updates
Monzo launches pension consolidation product
Neobanks
Yesterday
Precision Medicine

Precision Medicine

Jun 25, 2024

Proscia partners with Nucleai to expand AI biomarker solutions for precision medicine

Partnerships

  • Proscia has announced a collaboration with Nucleai to expand its precision medicine AI services and help optimize clinical trials and improve treatment decisions.

  • The collaboration involves integrating Nucleai’s predictive biomarker solutions into Proscia's software platform, Concentriq, as part of its precision medicine AI portfolio. This aims to help create an AI-guided roadmap of patient biopsies, aiding laboratories in optimizing clinical trials and matching patients to effective treatments and enabling pathologists and clinicians to convert data from patient biopsies into actionable insights to support better clinical trial and diagnostic decisions, potentially advancing next-generation treatment modalities such as ADCs, multi-specifics, immunotherapy, and combination therapies. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.